Thus, although IL-1 family cytokines remain attractive targets for IBD therapeutics, in order to fully resolve their role in IBD, additional studies utilizing cell-type-specific conditional knockout animals in which standardized protocols to limit the influence of inter-strain variances in the commensal microbiota are implemented will be required. Here, IL1B is linked to inflammatory bowel disease.